Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Hetero
30 Capsule in Bottle
Ibrutinib
Keep in cold place
Delivering To:
Overview
Nitib 140mg Capsule is used in the treatment of blood cancer (chronic lymphocytic leukemia) and mantle-cell lymphoma. Chronic lymphocytic leukaemia can also be treated with this medicine. Nitib 140mg Capsule is a prescription-based medicine. The cancer of white blood cells occurs when the body uncontrollably produces abnormal white blood cells, and the lymph nodes start growing in different body parts. It results in organ failure, a decrease in red blood cells, severe bleeding, and infections. The active ingredient of Nitib is Ibrutinib, which belongs to the drug class of antimetabolites. It is administered as an injection by an experienced nurse or medical professional. Nitib Capsule works by controlling the abnormal production of white blood cells.
Chronic lymphocytic leukemia, lymphocytic lymphoma
Blood cancer (Chronic lymphocytic leukemia)
Mantle-cell lymphoma
The human body reacts differently to Nitib 140mg Capsule. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Nitib 140mg Capsule are mentioned below: Some of the common side effects of Nitib Capsule are mentioned below:
High risk of infection
Vomiting
Weakness
Nausea
Fatigue
Fever
Decreased blood cells (red cells, white cells, and platelets)
Diarrhea
Cough
Take the dose of Nitib 140mg Capsule as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Nitib 140mg Capsule can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.
Nitib 140mg Capsule works by blocking the protein that is responsible for the multiplication of cancer cells. It is a Bruton's tyrosine kinase inhibitor. Furthermore, it slows or stops the growth of cancer cells.
Alcohol
consult your doctor
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Nitib 140mg Capsule. Consult your doctor for further information.
Pregnancy
consult your doctor
Nitib 140mg Capsule may be considered unsafe during pregnancy. Please consult your doctor in such a condition. According to some research data, taking Nitib 140mg Capsule during pregnancy has shown harmful effects on the developing baby.
Breast Feeding
consult your doctor
Nitib 140mg Capsule is probably not safe if you're breastfeeding. Kindly consult your doctor before taking Nitib 140mg Capsule while breastfeeding, as there are chances that it may pass to the developing baby through the breast milk of the mother.
Driving
unsafe
It is advisable not to drive or operate heavy machinery after taking Nitib 140mg Capsule, as you may feel dizzy.
Kidney
safe if prescribed
Share your medical history with your healthcare expert in case of kidney disease before taking Nitib 140mg Capsule. Patients with renal impairment must be careful while taking Nitib 140mg Capsule. They may require adjustment in the dose.
Liver
safe if prescribed
Inform your doctor before starting Nitib 140mg Capsule if you have liver disease to avoid any serious side effects. Patients with hepatic impairment must be careful while taking Nitib 140mg Capsule. They may require adjustment in the dose.
It is advised not to miss any scheduled dosage of Nitib 140mg Capsule. In case you miss a dose, consult your doctor immediately.
Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.
It is advised to use effective birth control methods and avoid pregnancy during the treatment with Nitib 140mg Capsule.
A person should avoid smoking while undergoing treatment with Nitib Capsule. Smoking may reduce the effectiveness of medicine.
Monitor your blood sugar & pressure, Kidney & Liver function (KFT & LFT), Heart function at proper intervals after taking Nitib.
Swelling of hands, lips, and weight gain are some of the side effects observed after taking this medicine. To reduce them, the doctor may suggest some medication.
Skin becomes extremely sensitive after taking Nitib 140mg Capsule. It is advised to cover your skin exposed to direct sun rays and use high SPF sunscreen before going out.
Keep your body hydrated as Diarrhea is one of the common side effects experienced after taking Nitib. Consult your doctor if it doesn't stop or if blood appears in your stools.
In case you notice symptoms like blurred vision, difficulty breathing, cough & fever, and diarrhea while taking this medicine, consult your doctor immediately before these symptoms become severe.
No, children below 18 years of age are not advised to take this medicine as it results in severe complications.
No, it is advised to avoid taking this medicine if you have serious kidney problems. Consult the doctor before taking this medication.
It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Nitib 140mg Capsule.
No, it is recommended to avoid taking this injection if the person has anemia or any blood-related disorder.
It is not safe to use this medicine during pregnancy as it causes harmful effects in the developing baby.
The Nitib 140mg Capsule may take days to a week to work properly. It depends on patients’ medical history, age, health condition, and the body's response to the treatment.
If you take extra doses of Nitib 140mg Capsule, then you should immediately go to the hospital emergency room or call your healthcare provider right away.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S.(2024). Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 387(10020):770-8.
Martin P. (2023). Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma? Lancet. 387(10020):728-9.
Killock D. (2025). Haematological cancer: Ibrutinib paves way to a brighter future in MCL. Nat Rev Clin Oncol. 13(2):65.
Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader KF, Laurell A, Toldbod H, Pedersen LB, Niemann CU, Dahl C, Kuitunen H, Geisler CH, Grønbæk K, Kolstad A. (2024). Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 5(3):e109-e116.
Steven P. Treon et al. (2024). Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol 39, 565-575(2021).
Roufarshbaf M, Javeri M, Akbari V, Matin PH, Farrokhi P, Sadeghi E, Heidari Z, Moghaddas A.(2025). Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis. Daru. 30(2):367-378.
Wang M, Jurczak W, Trneny M, Belada D, Wrobel T, Ghosh N, Keating MM, van Meerten T, Alvarez RF, von Keudell G, Thieblemont C, Peyrade F, Andre M, Hoffmann M, Szafer-Glusman E, Lin J, Dean JP, Neuenburg JK, Tam CS. (2024). Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 26(2):200-213.
Hetero
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.